INSM
Insmed IncorporatedNASDAQHealthcare$162.43-1.47%ClosedMarket Cap: $35.01B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
46.96
P/S
57.74
EV/EBITDA
-29.98
DCF Value
$-148.01
FCF Yield
-2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.4%
Operating Margin
-194.0%
Net Margin
-210.5%
ROE
-168.4%
ROA
-62.9%
ROIC
-64.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $263.8M | 82.5% | $-249.7M | $-328.5M | $-1.54 | — |
| FY 2025 | $606.4M | 79.4% | $-1.18B | $-1.28B | $-6.41 | — |
| Q3 2025 | $142.3M | 79.4% | $-366.0M | $-370.0M | $-1.75 | — |
| Q2 2025 | $107.4M | 73.9% | $-312.9M | $-321.7M | $-1.70 | — |
| Q1 2025 | $92.8M | 77.1% | $-248.1M | $-256.6M | $-1.42 | — |
| Q4 2024 | $104.4M | 75.0% | $-230.4M | $-235.5M | $-1.32 | — |
| FY 2024 | $363.7M | 76.4% | $-878.3M | $-913.8M | $-5.57 | — |
| Q3 2024 | $93.4M | 77.3% | $-213.4M | $-220.5M | $-1.27 | — |
| Q2 2024 | $90.3M | 76.8% | $-288.9M | $-300.6M | $-1.94 | — |
| Q1 2024 | $75.5M | 76.9% | $-145.5M | $-157.1M | $-1.06 | — |
| Q4 2023 | $83.7M | 78.0% | $-178.3M | $-186.1M | $-1.28 | — |
| FY 2023 | $305.2M | 78.5% | $-709.6M | $-749.6M | $-5.34 | — |